EMA Recommends Extending Indications for Durvalumab By Ogkologos - July 17, 2025 511 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Aumolertinib FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration MOST POPULAR What Cancer Survivors Should Know About Survivorship Research: Expert Perspectives January 26, 2024 Grace and Love for Full Hands March 31, 2021 FDA Approves Device for Treatment of Osteoid Osteoma in the Extremities December 1, 2020 EMA Recommends Granting a Marketing Authorisation for Generic Nilotinib August 16, 2024 Load more HOT NEWS How I Learned to Advocate for Myself During Cancer: “Your Stories”... Making a startup out of a scientist Metronomic Capecitabine as Adjuvant Therapy Provides Compelling Evidence In Locoregionally Advanced... The long road to targeting the holy grail of the immune...
